Buying Guide,structures

The precise survodutide structure is a key area of interest for researchers and clinicians investigating novel therapeutic approaches for metabolic disorders, particularly obesity. This novel glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist represents a significant advancement in the field, offering a unique mechanism of action rooted in its complex molecular architecture. Understanding its structure is fundamental to appreciating its potent pharmacological properties and its potential to address unmet medical needs.

At its core, survodutide is a peptide. More specifically, it is described as a 29-amino-acid peptide. This designation highlights its composition, built from a linear chain of amino acids linked by peptide bonds. The Protein Type is indeed PEPTIDE. This foundational characteristic dictates its biological behavior and how it interacts with target receptors in the body. The sequence of these amino acids is crucial for its three-dimensional folding and ultimately its biological activity. For example, the sequence has been noted to include structural modifications, such as a non-coded amino acid like 1-amino-1-cyclobutanecarboxylic acid at a specific position, which contributes to its optimized agonism for its target receptors.

Beyond its peptide backbone, the survodutide structure is further defined by its acylation. It is characterized as an acylated peptide with a C18 fatty acid conjugate. This means that a C18 fatty acid has been chemically attached to the peptide chain. This modification is not merely cosmetic; it plays a vital role in its pharmacokinetic profile, contributing to its long-acting nature. The attachment of this fatty acid moiety enhances lipophilicity, allowing the molecule to persist in the body for extended periods, thereby reducing the frequency of administration. This makes survodutide a long-acting glucagon/GLP-1 receptor dual agonist. The chemical structure of Survodutide can be represented by its molecular formula, C192H289N47O61, and its molecular weight is approximately 4231.63 g/mol, with an exact mass of 4229.0957.

The significance of the survodutide structure lies in its ability to act as a dual glucagon-like peptide-1 and glucagon receptor agonist activity. This dual agonism is a key differentiator, allowing it to engage with both the Glucagon-like peptide 1 receptor and the glucagon receptor (GCGR). This simultaneous activation of two critical metabolic pathways is believed to be responsible for its robust anti-obesity efficacy. By increasing energy expenditure and potentially reducing food intake, survodutide aims to achieve significant weight loss. The precise binding and activation of these receptors are intricately linked to the specific three-dimensional structures adopted by the peptide and its conjugate. Recent research has even utilized advanced techniques like cryogenic electron microscopy (cryo-EM) to determine the structures of GCGR and GLP-1R in complex with Survo and G protein at high resolution, offering unprecedented insights into the molecular interactions.

The concept behind survodutide is conceptually based on the endogenous peptide oxyntomodulin, making it an Oxyntomodulin analog. This connection to naturally occurring hormones further underscores its potential for physiological relevance. As a GLP1/GCGR agonist, its mechanism of action involves modulating glucose homeostasis and energy balance. The compound is often referred to by its developmental code, BI 456906, and is also known as survodutide acetate. Its classification as a hormone further emphasizes its role in regulating bodily functions.

In summary, the survodutide structure is a sophisticated molecular design featuring a 29-amino-acid peptide chain conjugated with a C18 fatty acid. This intricate structural makeup underpins its function as a potent dual glucagon-like peptide-1 and glucagon receptor agonist, offering a promising therapeutic avenue for individuals struggling with obesity and related metabolic conditions. The detailed understanding of its survodutide, including its precise chemical formula and its interaction with target receptors, is crucial for its continued development and eventual clinical application.